Navigation Links
GE Healthcare studies report results of [18F]Flutemetamol research
Date:7/20/2011

Chalfont St. Giles, UK, July 20, 2011 - Recent clinical research data reported that the investigational amyloid imaging agent [18F]Flutemetamol showed highly consistent image interpretation1 and showed comparable in vitro binding to the Pittsburgh Compound-B ([C-11]PiB)) investigational imaging agent3. Flutemetamol is a GE Healthcare Positron Emission Tomography (PET) investigational imaging agent currently in phase III development being studied for the detection of beta amyloid using PET brain scans.

The buildup of beta amyloid in the brain can lead to the degeneration of neurons and is one of several markers implicated in the development of AD. Currently, AD is typically confirmed by identifying the presence of tissue markers, including beta amyloid plaques, in post-mortem brain samples. Use of targeted imaging agents may help physicians detect amyloid deposition in live humans.

"These results should provide encouragement for patients and clinicians about the value of amyloid imaging in diagnosing AD," said Jonathan Allis, MI PET Segment Leader, GE Healthcare Medical Diagnostics. "Use of PET imaging scans to detect AD pathology may enable physicians to make a more accurate and earlier diagnosis of the disease."

Data highlights from three clinical abstracts to be featured at the 2011 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in Paris suggest that:

  • Flutemetamol reader training provided a highly consistent method for interpreting PET images. Readers blinded to clinical information demonstrated high inter- and intra-reader agreement rates when interpreting the brain distribution of Flutemetamol as normal and abnormal images.
  • Flutemetamol imaging was consistent with the understanding that normal pressure hydrocephalus (NPH), a progressive condition associated with dementia, gait abnormalities and urinary incontinence, represents a heterogeneous population with evidence of AD pathology.
  • 6-CN-Flutemetamol is comparable to 6-CN-Pittsburgh Compound-B (PiB) in its ability to bind to beta amyloid in vitro.

"At GE Healthcare, we are fully committed to developing products and tools that enable physicians to make confident medical decisions, allowing patients to get accurate diagnosis earlier in the process," said Pascale Witz, CEO, GE Healthcare Medical Diagnostics.

[18F]Flutemetamol is one part of a broad portfolio of diagnostic solutions that GE Healthcare is currently developing in the Alzheimer's field. The company is taking a comprehensive approach to understanding AD through its ongoing research to uncover the causes, risks and physical effects of the disease. GE Healthcare's global commitment to advance clinical knowledge and provide a variety of technologies to aid the fight in this epidemic may assist physicians in the acceleration of diagnosis and improvement of treatment decisions in all stages of the disease. The company already offers a range of imaging modalities used by physicians to assist in the detection of AD and dementia (CT, MRI, PET, SPECT) and has been a key contributor to the Alzheimer's Disease Neuroimaging Initiative since its inception. GE Healthcare also plays a key role in PredictAD, an EU-funded research project to develop solutions to enable earlier diagnosis of AD.


'/>"/>

Contact: Aleisia Gibson
Aleisia.gibson@ge.com
609-865-4004
Edelman Public Relations
Source:Eurekalert

Related biology news :

1. TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims
2. Phoenix conference highlights TGens and Scottsdale Healthcares contributions to molecular oncology
3. TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug
4. TGen-Scottsdale Healthcare researchers make breakthrough in lung cancer
5. GE Healthcare President & CEO, Mark Vachon, to Present at BioConference Live
6. GE Healthcare to evaluate and develop novel imaging technology
7. Scott & White Healthcare researcher finds success with new anti-cancer drug
8. Scott & White Healthcare researcher finds success with new anti-cancer drug
9. The Full Yield, Inc. Launches Breakthrough Collaboration to Put Food Back at the Heart of Healthcare
10. Inventor honored for tech improving access to clean water, healthcare, and business development in India
11. Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... , March 2, 2017 Who risk to ... Download the full report: https://www.reportbuyer.com/product/4313699/ ... FINGERPRINT SENSOR FIELD? Fingerprint sensors using capacitive technology ... fingerprint sensor vendor Idex forecasts an increase of 360% ... devices and of the fingerprint sensor market between 2014 ...
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , a ... globally, announces significant enhancements to new and core technologies ... New products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity ... technology provides the fastest and most accurate capture software ...
(Date:2/27/2017)...   Strategic Cyber Ventures , the industry,s first ... $3.5 million investment in  Polarity , the first commercial ... DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran and ... series A round of funding. This new funding will ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... MILFORD, Mass. , March 23, 2017 ... leading partner to global in vitro diagnostics ... launch of the industry,s first multiplexed ... inherited disease testing by next-generation sequencing ... materials were developed with input from industry ...
(Date:3/23/2017)... , March 23, 2017 Kineta, Inc., ... of novel therapies in immuno-oncology, today announced the ... small molecule compounds that activate interferon response factor ... and demonstrate immune-mediated tumor regression in a murine ... study who demonstrated complete tumor regression to initial ...
(Date:3/23/2017)... 23, 2017 In today,s pre-market ... in the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), ... MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." ... report at: ...
(Date:3/22/2017)... Denmark , March 22, 2017  Ascendis ... utilizes its innovative TransCon technology to address significant ... financial results for the full year ended December ... significant year for our company as we broadened ... a leading, integrated rare disease company with an ...
Breaking Biology Technology: